The Prefrontal Dectin-1/AMPA Receptor Signaling Pathway Mediates The Robust and Prolonged Antidepressant Effect of Proteo-[beta]-Glucan from Maitake

• Published in: Scientific reports Vol. 6; p. 28395
• Main Authors: Bao, Hongkun, Ran, Pengzhan, Zhu, Ming, Sun, Lijuan, Li, Bai, Hou, Yangyang, Nie, Jun, Shan, Liping, Li, Hongliang, Zheng, Shangyong, Xu, Xiufeng, Xiao, Chunjie, Du, Jing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 01.06.2016
• Subjects: Animals; Antidepressants; Mental depression; Pathophysiology; Phosphorylation; Beijing China; China
• ISSN: 2045-2322
• DOI: 10.1038/srep28395

Proteo-β-glucan from Maitake (PGM) is a strong immune regulator, and its receptor is called Dectin-1. Cumulative evidence suggests that AMPA receptors are important for the treatment of depression. Here, we report that PGM treatment leads to a significant antidepressant effect in the tail suspension test and forced swim test after sixty minutes of treatment in mice. After five consecutive days of PGM treatment, this antidepressant effect remained. PGM treatment did not show a hyperactive effect in the open field test. PGM significantly enhanced the expression of its receptor Dectin-1, as well as p-GluA1(S845) and GluA1, but not GluA2 or GluA3 in the prefrontal cortex (PFC) after five days of treatment. The Dectin-1 inhibitor Laminarin was able to block the antidepressant effect of PGM. At the synapses of PFC, PGM treatment significantly up-regulated the p-GluA1(S845), GluA1, GluA2, and GluA3 levels. Moreover, PGM's antidepressant effects and the increase of p-GluA1(S845)/GluA1 lasted for 3 days after stopping treatment. The AMPA-specific antagonist GYKI 52466 was able to block the antidepressant effect of PGM. This study identified PGM as a novel antidepressant with clinical potential and a new antidepressant mechanism for regulating prefrontal Dectin-1/AMPA receptor signalling.